Sistema de Salut de Catalunya
Institut Català de la Salut
[Meijs-Hermanns P] Maastricht University Medical Center, Department of Pathology, Maastricht, The Netherlands. [Werner HMJ] Maastricht University Medical Center, Department of Obstetrics and Gynecology, Maastricht, The Netherlands. GROW-School for Oncology and Reproduction, Maastricht, The Netherlands. [Kooreman L] Maastricht University Medical Center, Department of Pathology, Maastricht, The Netherlands. GROW-School for Oncology and Reproduction, Maastricht, The Netherlands. [Bretová P, Weinberger V] University Hospital Brno and Masaryk University, Department of Gynecology and Obstetrics, Brno, Czech Republic. [Vrede S] Radboud University Medical Center, Department of Obstetrics and Gynecology, Nijmegen, The Netherlands. [Gil-Moreno A] CIBERONC, Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca Biomèdica en Ginecologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERONC, Barcelona, Spain. Servei de Ginecologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-04-22T06:48:45Z
2025-04-22T06:48:45Z
2025-04
Endometrial carcinoma; Grade 2; Progesterone receptor
Carcinoma de endometrio; Grado 2; Receptor de progesterona
Carcinoma d'endometri; Grau 2; Receptor de progesterona
Objective This study aimed to evaluate the association between pre-operative progesterone receptor (PR) and p53 expression and prognosis in pre-operative grade 2 endometrioid endometrial carcinoma compared with grade 1 and grade 3 carcinomas. Methods Three European endometrial carcinoma cohort studies were included. Patients with pre-operative grade 2 endometrioid carcinoma and known pre-operative PR and p53 status were included (n = 400), as were patients with pre-operative grade 1 (n = 602) or grade 3 (n = 148) endometrioid carcinomas. Kaplan-Meier and Cox regression analyses were performed to analyze disease-specific and disease-free survival. Results Patients with pre-operative grade 2 endometrial carcinoma and wild-type p53 plus PR-positive expression showed a similar 7-year disease-specific survival to grade 1 endometrial carcinoma patients (95.8% vs 97.5%, p = .13), while the 7-year disease-specific survival of patients with grade 2 endometrial carcinoma with p53 aberrant and/or negative PR expression (83.5%) was significantly lower (p < .001). The combination of these markers was an independent prognostic factor in multivariate Cox regression analyses. Conclusions The prognostic impact of pre-operative p53 and PR expression in patients with grade 2 endometrioid endometrial carcinoma supports a modified binary grading system in which grade 2 patients should be pre-operatively classified as low- or high-grade depending on p53 and PR expression.
Artículo
Versión publicada
Inglés
Endometri - Càncer - Cirurgia; Endometri - Càncer - Prognosi; Progesterona - Receptors; Proteïnes supressores de tumors; DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Endometrial Neoplasms; Other subheadings::Other subheadings::Other subheadings::/surgery; DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Carcinoma, Endometrioid; Other subheadings::Other subheadings::Other subheadings::/surgery; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::Poly-ADP-Ribose Binding Proteins::Tumor Suppressor Protein p53; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Progesterone; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Neoplasm Grading; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias endometriales; Otros calificadores::Otros calificadores::Otros calificadores::/cirugía; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma::carcinoma endometrioide; Otros calificadores::Otros calificadores::Otros calificadores::/cirugía; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas transportadoras::proteínas de unión a poli-ADP-ribosa::proteína supresora de tumor p53; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::receptores citoplásmicos y nucleares::receptores de esteroides::receptores de progesterona; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::gradación neoplásica
Elsevier
International Journal of Gynecological Cancer;35(4)
https://doi.org/10.1016/j.ijgc.2025.101682
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]
